{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:57:58Z","timestamp":1781711878054,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Cancers affecting\u2009&lt;\u20096\/100,000\/year are classified as rare, but they account for up to 25% of all cancers and are associated with worse 5-year survival than common cancers. Early-phase clinical trials (EPCTs) may represent a viable treatment option for patients with rare cancers as they have evolved significantly with novel designs and the increasing use of precision medicine.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A retrospective study of patients with rare cancers referred to a large EPCT team at a UK specialist centre over 5 years (2016\u20132020) was conducted. Patient demographics, medical and oncological history, genomic variants, EPCT participation, responses and survival outcomes were analysed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In total, 240 patients with rare cancers were included. The mean age at diagnosis was 51.7 years (range 16\u201384), 54.2% of the patients were female. The most frequent rare cancers originated from the digestive system (27.1%), female genital tract (20%) and head and neck (H\u2009+\u2009N) (18.3%). Molecular profiling was offered to 45.5% of the population, median number of gene alterations was 3 per patient (range 1\u201320) while actionable gene alterations were reported in 60.2% (<jats:italic>n<\/jats:italic>\u2009=\u200950) of those with identified gene aberrations. Fifty-one patients participated in EPCTs, with 39.2% achieving SD and 11.8% PR. Median PFS for trial participants was three months (95% CI 1.12 \u2013 4.88) while median OS in the trial patients was 16\u00a0months (95% CI 9.10 \u2013 22.90) compared to 7 months for non-trial participants (95% CI 5.50 \u2013 8.51). Finally, poor Royal Marsden Hospital (RMH) prognostic score (2\u20133)\u00a0was correlated with worse survival when controlling for age and sex (HR 1.714, 95% CI 1.19 \u2013 2.46, <jats:italic>p<\/jats:italic>\u2009=\u20090.004).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Participation of patients with rare cancers in EPCTs may be associated with a survival benefit and lead to the development of new treatments for these patients. Moreover, expanded use of precision medicine is paramount as it can inform targeted treatment selection in this heterogenous group.\n<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-13934-2","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T14:55:06Z","timestamp":1743173706000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A single centre experience of patients with rare cancers referred for early phase clinical trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Angelos","family":"Angelakas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Krebs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Thistlethwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"issue":"8","key":"13934_CR1","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S1470-2045(17)30445-X","volume":"18","author":"G Gatta","year":"2017","unstructured":"Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet\u2014a population-based study. Lancet Oncol. 2017;18(8):1022\u201339.","journal-title":"Lancet Oncol"},{"issue":"4","key":"13934_CR2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3322\/caac.21400","volume":"67","author":"CE DeSantis","year":"2017","unstructured":"DeSantis CE, Kramer JL, Jemal A. The burden of rare cancers in the United States. CA Cancer J Clin. 2017;67(4):261\u201372.","journal-title":"CA Cancer J Clin"},{"issue":"17","key":"13934_CR3","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1016\/j.ejca.2011.08.008","volume":"47","author":"G Gatta","year":"2011","unstructured":"Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer. 2011;47(17):2493\u2013511.","journal-title":"Eur J Cancer"},{"issue":"4","key":"13934_CR4","first-page":"123","volume":"50","author":"BM Hofer","year":"2023","unstructured":"Hofer BM, Weir HK, Eckstrand A, Musonda K, Sherman R. The burden of rare cancers in North America. J Registry Manag. 2023;50(4):123\u201337.","journal-title":"J Registry Manag"},{"key":"13934_CR5","doi-asserted-by":"crossref","unstructured":"Casali PG, Trama A. Rationale of the rare cancer list: a consensus paper from the Joint Action on Rare Cancers (JARC) of the European Union (EU). ESMO Open. 2020;5(2):e000666.","DOI":"10.1136\/esmoopen-2019-000666"},{"issue":"6","key":"13934_CR6","first-page":"e13508","volume":"30","author":"SFA Duijts","year":"2021","unstructured":"Duijts SFA, Zwan JM. Rare cancers and cancer of unknown primary: here\u2019s what you should know! Eur J Cancer Care. 2021;30(6):e13508.","journal-title":"Eur J Cancer Care"},{"issue":"9","key":"13934_CR7","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.chembiol.2017.08.002","volume":"24","author":"T Sharifnia","year":"2017","unstructured":"Sharifnia T, Hong AL, Painter CA, Boehm JS. Emerging opportunities for target discovery in rare cancers. Cell Chem Biol. 2017;24(9):1075\u201391.","journal-title":"Cell Chem Biol"},{"key":"13934_CR8","unstructured":"European Society for Medical Oncology. Improving rare cancer care in Europe: recommendations on stakeholder actions and public policies. 2010. Available from: http:\/\/www.esmo.org\/content\/download\/16802\/296577\/file\/improving-rare-cancer-care-europerecommendations-2010.pdf."},{"issue":"11","key":"13934_CR9","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1158\/2159-8290.CD-21-0126","volume":"11","author":"P Horak","year":"2021","unstructured":"Horak P, Heining C, Kreutzfeldt S, Hutter B, Mock A, H\u00fcllein J, et al. Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Cancer Discov. 2021;11(11):2780\u201395.","journal-title":"Cancer Discov"},{"issue":"2","key":"13934_CR10","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/jrh.12693","volume":"39","author":"T Onega","year":"2023","unstructured":"Onega T, Alford-Teaster J, Leggett C, Loehrer A, Weiss JE, Moen EL, et al. The interaction of rurality and rare cancers for travel time to cancer care. J Rural Health. 2023;39(2):426\u201333.","journal-title":"J Rural Health"},{"issue":"1","key":"13934_CR11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s13023-021-01886-2","volume":"16","author":"E de Heus","year":"2021","unstructured":"de Heus E, Engelen V, Dingemans I, Richel C, Schrieks M, van der Zwan JM, et al. Differences in health care experiences between rare cancer and common cancer patients: results from a national cross-sectional survey. Orphanet J Rare Dis. 2021;16(1):249.","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"13934_CR12","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-019-0262-9","volume":"16","author":"JJ Adashek","year":"2019","unstructured":"Adashek JJ, Lorusso PM, Hong DS, Kurzrock R. Phase I trials as valid therapeutic options for patients with cancer. Nat Rev Clin Oncol. 2019;16(12):773\u20138.","journal-title":"Nat Rev Clin Oncol"},{"key":"13934_CR13","doi-asserted-by":"crossref","first-page":"775217","DOI":"10.3389\/fphar.2022.775217","volume":"13","author":"M Dooms","year":"2022","unstructured":"Dooms M, Saesen R, Steemans I, Lansens J, Huys I. Characteristics of early phase clinical trials for rare cancers: insights from interviews with stakeholders. Front Pharmacol. 2022;13: 775217.","journal-title":"Front Pharmacol"},{"issue":"2","key":"13934_CR14","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrclinonc.2015.194","volume":"13","author":"KM Wong","year":"2016","unstructured":"Wong KM, Capasso A, Eckhardt SG. The changing landscape of phase I trials in oncology. Nat Rev Clin Oncol. 2016;13(2):106\u201317.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"13934_CR15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1634\/theoncologist.2017-0199","volume":"23","author":"S Kato","year":"2018","unstructured":"Kato S, Kurasaki K, Ikeda S, Kurzrock R. Rare tumor clinic: the university of California San Diego Moores Cancer Center experience with a precision therapy approach. Oncologist. 2018;23(2):171\u20138.","journal-title":"Oncologist"},{"issue":"16","key":"13934_CR16","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.2008.19.5081","volume":"27","author":"HT Arkenau","year":"2009","unstructured":"Arkenau HT, Barriuso J, Olmos D, Ang JE, de Bono J, Judson I, et al. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol. 2009;27(16):2692\u20136.","journal-title":"J Clin Oncol"},{"issue":"6","key":"13934_CR17","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/sj.bjc.6604218","volume":"98","author":"HT Arkenau","year":"2008","unstructured":"Arkenau HT, Olmos D, Ang JE, de Bono J, Judson I, Kaye S. Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer. 2008;98(6):1029\u201333.","journal-title":"Br J Cancer"},{"key":"13934_CR18","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ejca.2017.07.027","volume":"84","author":"F Bigot","year":"2017","unstructured":"Bigot F, Castanon E, Baldini C, Hollebecque A, Carmona A, Postel-Vinay S, et al. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). Eur J Cancer. 2017;84:212\u20138.","journal-title":"Eur J Cancer"},{"issue":"23","key":"13934_CR19","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1056\/NEJMc1803837","volume":"378","author":"C Chakiba","year":"2018","unstructured":"Chakiba C, Grellety T, Bellera C, Italiano A. Encouraging trends in modern phase 1 oncology trials. N Engl J Med. 2018;378(23):2242\u20133.","journal-title":"N Engl J Med"},{"issue":"11","key":"13934_CR20","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jamaoncol.2016.2129","volume":"2","author":"M Schwaederle","year":"2016","unstructured":"Schwaederle M, Zhao M, Lee JJ, Lazar V, Leyland-Jones B, Schilsky RL, et al. Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis. JAMA Oncol. 2016;2(11):1452\u20139.","journal-title":"JAMA Oncol"},{"issue":"9","key":"13934_CR21","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMsa042220","volume":"352","author":"E Horstmann","year":"2005","unstructured":"Horstmann E, McCabe MS, Grochow L, Yamamoto S, Rubinstein L, Budd T, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med. 2005;352(9):895\u2013904.","journal-title":"N Engl J Med"},{"issue":"3","key":"13934_CR22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1001\/jamaoncol.2016.5299","volume":"3","author":"HJ West","year":"2017","unstructured":"West HJ. Novel precision medicine trial designs: umbrellas and baskets. JAMA Oncol. 2017;3(3):423.","journal-title":"JAMA Oncol"},{"issue":"8","key":"13934_CR23","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731\u20139.","journal-title":"N Engl J Med"},{"issue":"745","key":"13934_CR24","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3399\/bjgp24X738789","volume":"74","author":"SF Moore","year":"2024","unstructured":"Moore SF, Abel GA, Mounce LT. Challenges of diagnosing rare cancers in primary care. Br J Gen Pract. 2024;74(745):340\u20131.","journal-title":"Br J Gen Pract"},{"issue":"4","key":"13934_CR25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000080198","volume":"21","author":"J Weitz","year":"2004","unstructured":"Weitz J, Koch M, Friess H, Buchler MW. Impact of volume and specialization for cancer surgery. Dig Surg. 2004;21(4):253\u201361.","journal-title":"Dig Surg"},{"key":"13934_CR26","doi-asserted-by":"crossref","first-page":"103888","DOI":"10.1016\/j.critrevonc.2022.103888","volume":"181","author":"V Debien","year":"2023","unstructured":"Debien V, Vignot S, Massard C, Malouf G, Hollebecque A, Scoazec JY, et al. Molecular analysis for refractory rare cancers: Sequencing battle continues - learnings for the MOSCATO-01 study. Crit Rev Oncol Hematol. 2023;181: 103888.","journal-title":"Crit Rev Oncol Hematol"},{"key":"13934_CR27","unstructured":"Cancer Research UK. DETERMINE 2021. Available from: https:\/\/www.cancerresearchuk.org\/funding-for-researchers\/our-research-infrastructure\/our-centre-for-drug-development\/determine."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13934-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13934-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13934-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T14:56:35Z","timestamp":1743173795000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13934-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13934"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13934-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"30 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Overall approval as well as ethical approval for this study was received from the Quality Improvement and Clinical Audit Committee at the Christie NHS Foundation Trust for the study on 22nd April 2022 (reference 3299).As this was a retrospective study, consent to participate was not applicable and not required by the Quality Improvement and Clinical Audit Committee which provided approval for the project.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AA: None declared.NC: Financial Interests, Institutional, Invited Speaker: Roche, Taiho, AstraZeneca, RedX, Orion, Avacta, Bayer, Eisai, UCB, Starpharma, Boehringer Ingelheim, Stemline, Ergomed, LOXO Oncology, Nutide; Non-Financial Interests, Personal, Advisory Role: Roche.DMG: Financial Interests, Personal, Advisory Board, Consulting role on advisory board: Clinigen; Financial Interests, Personal, Invited Speaker: Cancer Drug Development Fund; Financial Interests, Personal, Advisory Board: McCann Health; Financial Interests, Institutional, Invited Speaker, Institutional funding from study: MSD, Codiak Biosciences, Starpharma, Faron Pharmaceuticals, Synthon, Janssen, Incyte; Financial Interests, Institutional, Research Grant: AstraZeneca.MK: Financial Interests, Personal, Advisory Board: Bayer, Roche, Janssen, Guardant Health; Financial Interests, Personal, Invited Speaker: Roche, Janssen; Financial Interests, Institutional, Expert Testimony: AstraZeneca; Financial Interests, Institutional, Advisory Board: Seattle Genetics; Financial Interests, Institutional, Invited Speaker: AstraZeneca, Blueprint, Astex, Bayer, BerGenBio, Carrick, Immutep, Janssen, Novartis, Nurix, Nuvalent, Pyramid Biosciences, Roche, Seattle Genetics, Turning Point Therapeutics; Financial Interests, Institutional, Research Grant: Roche, Novartis; Other, Personal, Other, Travel expenses for congress: Immutep, Janssen.FT: Financial interests, Personal, Advisory Board: BMS, CytomX, F-Star, Grey Wolf Therapeutics, GSK, Immatics, Leucid, Scenic Biotech, T-Knife Therapeutics; Financial interests, Personal, Invited Speaker: Kite Gilead; Financial interests, Personal, Other, Consultancy: Guidepoint; Financial interests, Institutional, Other: iMATCH director; Financial interests, Institutional, Local PI: Achilles ltd, Adaptimmune, Agalimmune Ltd, BMS, Crescendo, CytomX, GenMab, Immunocore, Incyte, Janssen, Novalgen, Novartis, Nucana, Oxford Vacmedix Ltd, Pfizer, RS Oncology LLC; Financial interests, Institutional, Coordinating PI: ADCT Therapeutics, Chugai, GSK, Instil Bio, Kymab Ltd\/Sanofi, Roche; Financial interests, Institutional, Research Grant: GSK, Novartis, Autolus, Gilead; Non-financial interests, Institutional, Coordinating PI: T-Knife Therapeutics, AstraZeneca; Non-financial interests, Personal, Leadership role: Chair of the Independent Steering Committee for NIHR Blood & Transplant Research Unit, ESMO Congress 2024 Experimental Immunotherapy Track Chair, MRC Advanced Therapies Task Group, CRUK New Agents Committee Member, ESMO TAT conference scientific advisory board 2025, Sarcoma UK, Target Ovarian Cancer.LC: Financial Interests, Personal, Other, Consultancy: Bicycle Therapeutics, Boehringer Ingelheim, Athenex; Financial Interests, Personal, Full or part-time Employment, Medical Advisor: Cancer Research UK Centre for Drug Development; Financial Interests, Institutional, Invited Speaker: Boehringer Ingelheim, Bicycle Therapeutics, Cellcentric, Eli Lilly, Athenex, Lupin Limited, Repare Therapeutics, Cytomx therapeutics, EMD Serono\/Merck KGaA, Sierra Oncology.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"558"}}